{"id":2710,"date":"2026-08-26T13:00:00","date_gmt":"2026-08-26T17:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2710"},"modified":"2026-08-26T23:52:51","modified_gmt":"2026-08-27T03:52:51","slug":"fmnl1-overexpression-improves-car-t-tumor-trafficking-in-mouse-models","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2710","title":{"rendered":"FMNL1 Overexpression Improves CAR-T Tumor Trafficking in Mouse Models"},"content":{"rendered":"

Institution:<\/strong> University of Colorado · Target:<\/strong> FMNL1 Overexpression · Modality:<\/strong> CAR-T \/ TIL Cytoskeletal Engineering · Models:<\/strong> Murine Melanoma, Lung Carcinoma · Date:<\/strong> August 25, 2026 (preprint)<\/p>\n

\"20260826_University_of_Colorado_FMNL1_CAR_T_Technology_and_Modalities\"<\/p>\n

Summary<\/h4>\n

A University of Colorado-led preprint reports that overexpressing the actin regulator Formin-like 1 (FMNL1) in tumor-specific T cells increases accumulation in restrictive solid tumors and improves antitumor activity in mouse models. The intervention is designed to strengthen the physical migration machinery of tumor-infiltrating lymphocytes and CAR-T cells rather than alter antigen recognition, making the concept potentially portable across constructs. All therapeutic evidence remains preclinical, and safety, manufacturing compatibility and human trafficking are unresolved.<\/p>\n

What Happened<\/h4>\n

The team engineered tumor-specific TILs and CAR-T cells to overexpress FMNL1, a formin that supports actin polymerization and nuclear deformation during migration through confined environments; engineered cells retained activation and tumor-cell killing in vitro, suggesting the manipulation did not obviously compromise baseline effector function in the reported assays. In murine melanoma and lung-carcinoma models, FMNL1-overexpressing cells accumulated more strongly at tumor sites than control cells, and in melanoma, CAR-T treatment prolonged survival in both immunodeficient and immunocompetent recipients. The work extends an April 2026 conference abstract and earlier peer-reviewed studies showing that FMNL1 is required for effector T-cell movement through restrictive barriers. The August 25 manuscript is a preprint and has not undergone peer review; no human biodistribution, tumor-biopsy, persistence, dose-response, cytokine, on-target\/off-tissue or manufacturing-release data were identified, and the authors disclose a related University of Colorado patent application.<\/p>\n

Deep Analysis<\/h4>\n

Solid tumors create a mechanical access problem through abnormal vasculature, dense extracellular matrix, high interstitial pressure and confined spaces. FMNL1 engineering addresses this bottleneck at the cell-motility layer, and because it does not depend on a particular CAR or antigen, it could in principle complement logic gating, armoring, checkpoint resistance or chemokine-receptor strategies. More migration is not automatically safer or more effective, however: a globally enhanced ability to traverse barriers could increase entry into inflamed healthy tissues, amplify antigen-dependent off-tumor injury, or alter retention and recirculation. The same cytoskeletal changes may also affect immune synapse dynamics, proliferation, exhaustion, differentiation or susceptibility to mechanical stress over repeated encounters.<\/p>\n

Translation requires a manufacturable expression system with consistent FMNL1 level, stable phenotype and no unacceptable insertional or genomic risk. Comparative studies must show that added trafficking translates into tumor control after controlling for cell dose, expansion and persistence, and that the gain is not restricted to transplantable mouse tumors with unusually permissive biology.<\/p>\n

Company and Product Background<\/h4>\n

FMNL1 is a leukocyte-enriched formin that nucleates and elongates linear actin filaments and helps T cells deform their nuclei in confined spaces. CAR-T cells can eliminate several hematologic cancers, but solid-tumor activity is constrained by antigen heterogeneity, suppressive signaling, exhaustion, limited persistence and physical exclusion from tumor tissue. Current trafficking approaches include chemokine-receptor matching, extracellular-matrix remodeling, vascular targeting and local delivery; cytoskeletal engineering is differentiated because it alters the cell’s migration machinery directly, and its competitive value would require additive benefit, controllability and safety relative to those approaches, not merely higher tumor-cell counts in mice.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Mechanism<\/td>\nFMNL1 strengthens actin-dependent migration through restrictive environments<\/td>\n<\/tr>\n
Tumor Access<\/td>\nGreater TIL and CAR-T accumulation in murine melanoma and lung carcinoma<\/td>\n<\/tr>\n
Activity<\/td>\nLonger survival in melanoma models with engineered CAR-T cells (mouse data only)<\/td>\n<\/tr>\n
Portability<\/td>\nAntigen- and CAR-construct-independent design rationale<\/td>\n<\/tr>\n
Safety\/IP<\/td>\nRelated patent application disclosed; off-tissue trafficking risk unresolved<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Cytoskeletal engineering is a modular way to relieve a physical bottleneck that many solid-tumor cell therapies share, with results across TILs, CAR-T cells and more than one tumor model supporting a real, construct-independent motility effect.<\/p>\n

Bear case:<\/strong> FMNL1 may mainly improve performance in specific murine barriers and could introduce broad trafficking liabilities in humans; the absence of human tissue, safety and long-duration data means the therapeutic window remains entirely unestablished.<\/p>\n

InSilens Take<\/h4>\n

FMNL1 overexpression reframes solid-tumor access as an engineerable mechanical property of the therapeutic cell and shows multi-model preclinical activity. The concept is not treatment-ready: the decisive questions are whether enhanced migration remains tumor-directed, survives manufacturing and repeated antigen exposure, and improves human tumor control without expanding off-tissue risk.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> Moderate-High on facts, Low-Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

A University of Colorado-led preprint reports that overexpressing the actin regulator Formin-like 1 (FMNL1) in tumor-specific T cells increases accumulation in restrictive solid tumors and improves antitumor activity in mouse models. The intervention is…<\/p>\n","protected":false},"author":1,"featured_media":2715,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[377,439,68,440],"class_list":["post-2710","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-car-t-cell-therapy-2","tag-fmnl1","tag-solid-tumors","tag-t-cell-trafficking"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2710"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2710\/revisions"}],"predecessor-version":[{"id":2720,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2710\/revisions\/2720"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2715"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}